Chief Marketing Officer, Human Health · Merck & Co., Inc. (MRK)

Chirfi Guindo

FY2022 is the first fiscal year CompBrief holds for Chirfi Guindo as a named executive officer of Merck; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$13,937,264

Salary $348,077Stock awards $12,395,556Bonus $530,000

2nd of 6 named executive officers at Merck by FY2022 total.

6 named officers on file for Merck, FY2022

Chirfi Guindo’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • MRK’s disclosed peer group of 12 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Merck’s whole pay program stands against its peers

  • Merck’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MRK→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 3, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Chirfi Guindo’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Chirfi Guindo compensation by year

Merck Summary Compensation Table · the one fiscal year held
In US dollars, as Merck reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$348,077
Bonus$530,000
Stock awards$12,395,556
Option awards$0
Non-equity incentive$502,496
Pension and deferred compensation$0
All other$161,135
Total$13,937,264

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Merck & Co., Inc. DEF 14A filed April 3, 2023, accession 0001193125-23-089525, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Merck & Co., Inc. filed document, accession 0001193125-23-089525. Every figure is read from that document and cited to the page and table it appears in. Filed April 3, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU110,705$12,282,720—
PSU57,064$6,331,251—

Per the Outstanding Equity Awards at Fiscal Year-End table in Merck & Co., Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

17 Form 4 lines since the FY2022 proxy (filed April 3, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-08-13Sale—10,000$135.0036,613.13
2026-08-06Sale—15,000$131.0046,613.13
2026-05-05Grant or award derivative—6,628$0.006,628
2026-05-05Grant or award derivative—19,402$0.0019,402
2026-04-29Exercise or conversion derivative—1,967$0.003,935
2026-04-29Exercise or conversion—1,967$110.0362,582.13
2026-04-29Tax withholding—969$110.0361,613.13
2026-02-12Sale—10,000$121.4660,615.13

The 8 most recent of 17 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments Merck discloses, by trigger · FY2022
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$350,000$18,613,971$9,836$18,978,457
Change in control and involuntary termination$2,520,000$15,448,345$39,342$18,022,337

Per the Potential Payments Upon Termination or Change in Control table in Merck & Co., Inc.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.

Merck’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Robert DavisChairman, Chief Executive Officer and President$18,650,093
Chirfi Guindo · this pageChief Marketing Officer, Human Health$13,937,264
Kenneth FrazierFormer Executive Chairman$8,510,621
Dean LiExecutive Vice President and President, Merck Research Laboratories$7,766,063
Jennifer ZacharyExecutive Vice President and General Counsel$5,896,628
Caroline LitchfieldExecutive Vice President and Chief Financial Officer$5,702,438

The full Merck compensation record

free company brief

This page is one person within Merck's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Merck proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Merck's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Chirfi Guindo's compensation dossier · One-time report. No refunds.